Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry
- 1 May 2004
- journal article
- Published by Oxford University Press (OUP) in The Quarterly Journal of Economics
- Vol. 119 (2) , 527-564
- https://doi.org/10.1162/0033553041382166
Abstract
Public policies designed to increase utilization of existing technologies may also affect incentives to develop new technologies. This paper investigates this phenomenon by examining policies designed to increase usage of preexisting vaccines. I find that these policies were associated with a 2.5-fold increase in clinical trials for new vaccines. For several diseases, the induced innovation is socially wasteful, though small in magnitude. In one case, however, the “dynamic” social welfare benefits from induced innovation exceed the policies' “static” benefits from increasing vaccination with existing technology. These findings underscore the importance of including technological progress in economic analysis of public policy.Keywords
This publication has 8 references indexed in Scilit:
- Vaccination policies and programs: The federal government's role in making the system workPrimary Care: Clinics in Office Practice, 2001
- Creating Markets for New Vaccines. Part I: RationaleInnovation Policy and the Economy, 2000
- New technologies for making vaccinesVaccine, 1999
- Your Money and Your Life: The Value of Health and What Affects ItPublished by National Bureau of Economic Research ,1999
- Vaccine R&D success rates and development timesNature Biotechnology, 1996
- Medical Care Costs: How Much Welfare Loss?Journal of Economic Perspectives, 1992
- Cost of innovation in the pharmaceutical industryJournal of Health Economics, 1991
- Invention and Economic GrowthPublished by Harvard University Press ,1966